Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. Issue 11 (20th July 2020)

• Record Type: Journal Article
• Authors: Yu, Jin-Tai; Xu, Wei; Tan, Chen-Chen; Andrieu, Sandrine; Suckling, John; Evangelou, Evangelos; Pan, An; Zhang, Can; Jia, Jianping; Feng, Lei; Kua, Ee-Heok; Wang, Yan-Jiang; Wang, Hui-Fu; Tan, Meng-Shan; Li, Jie-Qiong; Hou, Xiao-He; Wan, Yu; Tan, Lin; Mok, Vincent; Tan, Lan; Dong, Qiang; Touchon, Jacques; Gauthier, Serge; Aisen, Paul S; Vellas, Bruno
• Is Part Of: Journal of neurology, neurosurgery and psychiatry. Volume 91:Issue 11(2020)
• Page Start: 1201
• Page End: 1209
• Publication Date: 2020-07-20
• Subjects: alzheimer's disease -- epidemiology -- meta-analysis -- systematic reviews; Neurology -- Periodicals; Nervous system -- Surgery -- Periodicals; Psychiatry -- Periodicals; 616.8
• DOI: 10.1136/jnnp-2019-321913
• Languages: English
• ISSNs: 0022-3050

Abstract

Abstract : Background: Evidence on preventing Alzheimer's disease (AD) is challenging to interpret due to varying study designs with heterogeneous endpoints and credibility. We completed a systematic review and meta-analysis of current evidence with prospective designs to propose evidence-based suggestions on AD prevention. Methods: Electronic databases and relevant websites were searched from inception to 1 March 2019. Both observational prospective studies (OPSs) and randomised controlled trials (RCTs) were included. The multivariable-adjusted effect estimates were pooled by random-effects models, with credibility assessment according to its risk of bias, inconsistency and imprecision. Levels of evidence and classes of suggestions were summarised. Results: A total of 44 676 reports were identified, and 243 OPSs and 153 RCTs were eligible for analysis after exclusion based on pre-decided criteria, from which 104 modifiable factors and 11 interventions were included in the meta-analyses. Twenty-one suggestions are proposed based on the consolidated evidence, with Class I suggestions targeting 19 factors: 10 with Level A strong evidence (education, cognitive activity, high body mass index in latelife, hyperhomocysteinaemia, depression, stress, diabetes, head trauma, hypertension in midlife and orthostatic hypotension) and 9 with Level B weaker evidence (obesity in midlife, weight loss in late life, physical exercise, smoking, sleep, cerebrovascular disease, frailty, atrial fibrillation and vitamin C). In contrast, two interventions are not recommended: oestrogen replacement therapy (Level A2) and acetylcholinesterase inhibitors (Level B). Interpretation: Evidence-based suggestions are proposed, offering clinicians and stakeholders current guidance for the prevention of AD.